Drug General Information (ID: DDIKEV350L)
Drug Name			Irinotecan (liposomal)		Drug Info		Panitumumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Irinotecan (liposomal)-Panitumumab Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Irinotecan (liposomal)				Panitumumab
Mechanism		Diarrhea				Diarrhea
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Irinotecan (liposomal) and Panitumumab

Recommended Action
Management		Due to a high incidence of severe diarrhea, which may lead to electrolyte depletion and acute renal failure, the use of panitumumab in combination with the IFL regimen should generally be avoided. Patients treated with panitumumab should be monitored for signs and symptoms of severe diarrhea and dehydration such as decreased urine output, dizziness, low blood pressure, and rapid heartbeat. Appropriate medical therapy should be rendered promptly as necessary for the treatment of these complications, and panitumumab withheld until the patient recovers.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Vectibix (panitumumab). Amgen USA, Thousand Oaks, CA.